Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Treatment-naive Advanced Non-small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 0 results

Large-scale testing (Phase 3)UnknownNCT00006048
What this trial is testing

ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
AstraZeneca
Large-scale testing (Phase 3)Not Yet RecruitingNCT06254599
What this trial is testing

SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Shouyao Holdings (Beijing) Co. LTD 255
Testing effectiveness (Phase 2)Study completedNCT00077246
What this trial is testing

ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center 64
Early research (Phase 1)Ended earlyNCT06546553
What this trial is testing

Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

Who this might be right for
NeoplasmsNon-small-cell Lung CancerSquamous Cell Carcinoma of the Head and Neck+3 more
Pfizer 10
Large-scale testing (Phase 3)Study completedNCT02075840
What this trial is testing

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 303
Testing effectiveness (Phase 2)Active Not RecruitingNCT02638090
What this trial is testing

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Lung CancerNon-small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 120
Testing effectiveness (Phase 2)Study completedNCT00518011
What this trial is testing

Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 17
Testing effectiveness (Phase 2)UnknownNCT05675033
What this trial is testing

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Who this might be right for
Lung AdenocarcinomaStage IV Non-small Cell Lung CancerPD-1 Inhibitor+1 more
Fujian Cancer Hospital 50
Testing effectiveness (Phase 2)Study completedNCT00005037
What this trial is testing

Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
Fox Chase Cancer Center 51
Testing effectiveness (Phase 2)Study completedNCT02013206
What this trial is testing

Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 52
Testing effectiveness (Phase 2)Study completedNCT02108964
What this trial is testing

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Who this might be right for
Advanced Non-small Cell Lung Cancer
Novartis Pharmaceuticals 225
Large-scale testing (Phase 3)Study completedNCT01853826
What this trial is testing

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 481